Palleon Pharmaceuticals

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced the revision of a cooperation and licensing agreement initially signed with Palleon Pharmaceuticals Inc. in June 2022. The original agreement was centered around the development of a bifunctional anti-HER2 antibody-sialidase fusion protein and a second…